Lung cancer (Amsterdam, Netherlands) · 2026
Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Masfarré Laura, Parreira Ana Sofia, Castro Natalia, Miquel Claudia, Navarro-Gorro Nil, Fabregat Raquel Marse, Bellvert Cristina Gomez, Fernandez Amaia Ariño, Serra Antonia Company, Aguillo Maite Martinez, Arasanz Hugo, Teijeira Lucia, Morilla Idoia, Rocha Pedro, Galindo Miguel, Clave Sergi, Taus Alvaro, Martinez Aitor Azkarate, Arriola Edurne
Аннотация
BACKGROUND: KRAS is the most heterogeneous and frequent oncogenic driver in non-small cell lung cancer (NSCLC). KRAS alleles and co-mutations shape the tumour microenvironment, potentially influencing benefit from immune checkpoint inhibitors (ICI). The aim of our study was to evaluate the patterns of KRAS mutations, their correlation with clinical and pathological features and their association with ICI outcomes.
METHODS: We conducted a multicentre retrospective analysis of patients with advanced KRAS-mutant NSCLC treated with ICI. Clinical, pathological and molecular data were collected, including KRAS mutation type (G12C vs non-G12C), key co-mutations and PD-L1 expression. These variables were correlated with clinical outcomes. Survival outcomes were analysed using Kaplan-Meier estimates and multivariate Cox regression models.
RESULTS: A total of 198 patients with KRAS mutant NSCLC were evaluated, with 49.5% carrying a G12C mutation. Overall, 81% of patients received first-line ICI, either as monotherapy or combined with chemotherapy. After a median follow-up of 48 months, G12C cases showed significantly longer median overall survival (OS) (15 vs 9 months; HR 0.71; p = 0.031). Multivariate analysis indicated that G12C mutations correlated with improved OS, as well as good performance status and absence of central nervous system (CNS) metastases.
CONCLUSIONS: In this retrospective real-world cohort, KRAS mutation subtype was associated with differences in ICI outcomes, particularly OS. These findings should be considered hypothesis-generating and warrant prospective validation in molecularly characterized cohorts.
METHODS: We conducted a multicentre retrospective analysis of patients with advanced KRAS-mutant NSCLC treated with ICI. Clinical, pathological and molecular data were collected, including KRAS mutation type (G12C vs non-G12C), key co-mutations and PD-L1 expression. These variables were correlated with clinical outcomes. Survival outcomes were analysed using Kaplan-Meier estimates and multivariate Cox regression models.
RESULTS: A total of 198 patients with KRAS mutant NSCLC were evaluated, with 49.5% carrying a G12C mutation. Overall, 81% of patients received first-line ICI, either as monotherapy or combined with chemotherapy. After a median follow-up of 48 months, G12C cases showed significantly longer median overall survival (OS) (15 vs 9 months; HR 0.71; p = 0.031). Multivariate analysis indicated that G12C mutations correlated with improved OS, as well as good performance status and absence of central nervous system (CNS) metastases.
CONCLUSIONS: In this retrospective real-world cohort, KRAS mutation subtype was associated with differences in ICI outcomes, particularly OS. These findings should be considered hypothesis-generating and warrant prospective validation in molecularly characterized cohorts.